Sidley Austin and Moelis & Company have advised ARCHIMED. Goodwin Procter and Centerview Partners have advised Esperion Therapeutics. Akin Gump has advised Pharmakon Advisors. ARCHIMED, a...
ARCHIMED Acquires Esperion Therapeutics in $1.1 Billion Transaction
Lilly Acquires Centessa Pharmaceuticals for Up to $7.8 Billion to Bolster Neuroscience Portfolio
Kirkland & Ellis has advised Eli Lilly and Company. Goodwin Procter and Wilson Sonsini Goodrich & Rosati have advised Centessa Pharmaceuticals plc. Eli Lilly and Company...
Merck’s $3.9 Billion Acquisition of SpringWorks Therapeutics
Sullivan & Cromwell advised Merck KGaA, Darmstadt, Germany, while Goodwin Procter advised SpringWorks Therapeutics on the transaction. Skadden advised Centerview Partners and Goldman Sachs & Co....
Novartis’ $3.1 Billion Acquisition of Anthos Therapeutics
Goodwin Procter and Ropes & Gray represented Anthos Therapeutics in the transaction. Novartis announced its acquisition of Anthos Therapeutics, Inc. for up to $3.1 billion. Under...
Collegium Pharmaceutical’s $525 Million Acquisition Of Ironshore Therapeutics
Lazard is acting as the exclusive financial advisor to Collegium. Hogan Lovells is serving as M&A legal counsel to Collegium. Goodwin Procter LLP is serving as...
Merck’s $680 Million Acquisition of Harpoon Therapeutics
Evercore Group L.L.C. acted as financial advisor to Merck in this transaction and Covington & Burling LLP acted as its legal advisor. Centerview Partners LLC acted...
Synopsys’ Acquisition of ANSYS
Cleary Gottlieb Steen & Hamilton is representing Synopsys, while Skadden and Goodwin Procter are representing ANSYS on the deal. Synopsys, Inc. (Synopsys) announced its acquisition of...
Bristol Myers Squibb’s $4.1 Billion Acquisition of RayzeBio
Covington advised Bristol Myers Squibb on the transaction, while Cooley and Wilson Sonsini Goodrich & Rosati advised RayzeBio Inc. Goodwin advised Centerview Partners in its role...
AstraZeneca’s $1.1 Billion Acquisition of Icosavax
Centerview Partners LLC is serving as exclusive financial advisor to Icosavax and Goodwin is serving as legal counsel. Icosavax, Inc. (Nasdaq: ICVX) announced it has entered...
Generate:Biomedicines’ $273 Million Series C Funding Round
Goodwin advised Generate:Biomedicines on the fundraising. Generate:Biomedicines announced that it has raised $273 million in Series C financing. This financing round attracted many new investors including...
Revolution Medicines’ Acquisition of EQRx
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
Evelo Biosciences’ $25.5 Million Private Placement
Goodwin advised Flagship Pioneering on the investment. Evelo Biosciences, Inc. (Nasdaq:EVLO) announced a securities purchase agreement with investors in a private placement to sell 11,025,334 shares of...